- ISIN
- CA98985W1023
- CUSIP
- 98985W102
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Apr 28, 2017
Highlights
- Market Cap
- $1.78B
- Enterprise Value
- -$222.18B
- EPS (TTM)
- -$583.41
- Total Revenue (TTM)
- $78.86M
- Gross Profit (TTM)
- $77.16M
- EBITDA (TTM)
- -$47.18B
- Year Range
- $11.51 - $29.75
- Target Price
- $38.33
- ROA (TTM)
- -9.25%
- ROE (TTM)
- -27.03%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ZYME Performance Chart
Zymeworks Inc. (ZYME) is down 9.3% since the beginning of the year. At $24 per share, ZYME is trading 19.7% below its 52-week high of $30. Investors who bought $1,000 worth of ZYME shares 5 years ago would now be looking at an investment worth $651.
Loading charts...
Returns By Period
Zymeworks Inc. (ZYME) has returned -9.30% so far this year and 91.50% over the past 12 months.
Zymeworks Inc.
- 1D
- 2.67%
- 1M
- -6.76%
- YTD
- -9.30%
- 6M
- -10.86%
- 1Y
- 91.50%
- 3Y*
- 43.33%
- 5Y*
- -8.24%
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -1.44%
- 1M
- -1.45%
- YTD
- 7.60%
- 6M
- 6.59%
- 1Y
- 22.24%
- 3Y*
- 19.20%
- 5Y*
- 11.54%
- 10Y*
- 13.71%
ZYME Monthly Returns History
Based on dividend-adjusted daily data since Apr 28, 2017, ZYME's average daily return is +0.10%, while the average monthly return is +1.88%. At this rate, an investment would double in approximately 3.1 years.
Historically, 53% of months were positive and 47% were negative. The best month was Jan 2018 with a return of +73.7%, while the worst month was Jan 2022 at -45.7%. The longest winning streak lasted 7 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ZYME closed higher 50% of trading days. The best single day was Nov 17, 2025 with a return of +29.1%, while the worst single day was Sep 6, 2022 at -28.9%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | -14.43% | 3.37% | 7.51% | 9.98% | -8.75% | -4.97% | -9.30% | ||||||
| 2025 | -0.27% | -8.22% | -11.12% | 9.24% | -12.14% | 9.80% | 0.08% | 17.91% | 15.33% | 11.74% | 39.95% | -1.42% | 79.85% |
| 2024 | 4.33% | 10.79% | -12.41% | -18.44% | -1.17% | 0.35% | 22.91% | 12.14% | 6.99% | 9.16% | 2.85% | 3.90% | 40.90% |
| 2023 | 20.23% | -13.02% | 9.98% | -7.08% | -2.02% | 4.98% | -13.66% | -2.95% | -12.43% | 10.73% | 26.35% | 17.14% | 32.19% |
| 2022 | -45.70% | -18.65% | -9.53% | -6.72% | 9.98% | -21.13% | 10.19% | 9.76% | -4.06% | 20.81% | 3.90% | 1.81% | -52.04% |
| 2021 | -28.44% | 7.36% | -13.03% | 2.98% | -4.06% | 11.19% | -7.49% | 2.80% | -11.97% | -23.38% | -9.62% | -18.50% | -65.32% |
Benchmark Metrics
Zymeworks Inc. has an annualized alpha of 12.85%, beta of 0.92, and R2 of 0.08 versus S&P 500 Index. Calculated based on daily prices since April 28, 2017.
- This stock participated in 126.27% of S&P 500 Index downside but only 100.63% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.08 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- 12.85%
- Beta
- 0.92
- R²
- 0.08
- Upside Capture
- 100.63%
- Downside Capture
- 126.27%
Return for Risk
Risk / Return Rank
ZYME ranks 87 for risk / return — in the top 87% of stocks on our site. This means strong returns relative to risk — exactly what professional investors look for. Well-suited for investors who want to maximize return per unit of risk.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Zymeworks Inc. (ZYME) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ZYME | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.04 | ||
| Sortino ratioReturn per unit of downside risk | +0.26 | ||
| Omega ratioGain probability vs. loss probability | 1.33 | 1.32 | +0.01 |
| Calmar ratioReturn relative to maximum drawdown | 4.33 | 2.46 | +1.87 |
| Martin ratioReturn relative to average drawdown | 9.21 | 10.92 | -1.71 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Zymeworks Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Zymeworks Inc. was 91.81%, occurring on Sep 7, 2022. The portfolio has not yet recovered.
The current Zymeworks Inc. drawdown is 57.97%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
Bear market2022 | -91.81%Sep 2022 | 1y 7mo | — | 5y 5moJan 2021 - now |
2017 bear market2017 | -52.00%Aug 2017 | 3mo 11d | 8mo 22d | 12mo 3dApr 2017 - Apr 2018 |
COVID crash2020 | -51.24%Mar 2020 | 1mo 23d | 8mo 16d | 10mo 9dJan 2020 - Nov 2020 |
Rate-hike selloffLate 2018 | -49.91%Dec 2018 | 6mo 20d | 6mo 5d | 1y 20dJun 2018 - Jun 2019 |
2019 correction2019 | -14.72%Sep 2019 | 21d | 17d | 1mo 8dSep 2019 - Oct 2019 |
Drawdown Indicators
| ZYME | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -91.81% | -56.78% | -35.03% |
Max Drawdown (1Y)Largest decline over 1 year | -21.25% | -9.10% | -12.15% |
Max Drawdown (3Y)Largest decline over 3 years | -45.75% | -18.90% | -26.85% |
Max Drawdown (5Y)Largest decline over 5 years | -87.53% | -25.43% | -62.10% |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -57.97% | -3.21% | -54.76% |
Average DrawdownAverage peak-to-trough decline | -52.54% | -10.71% | -41.83% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 9.97% | 2.04% | +7.93% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Zymeworks Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Zymeworks Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ZYME relative to other companies in the Biotechnology industry. Currently, ZYME has a P/S ratio of 23.0. This P/S ratio falls within the average range for the industry, suggesting the stock is fairly valued based on its revenue.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ZYME in comparison with other companies in the Biotechnology industry. Currently, ZYME has a P/B value of 0.0. This P/B ratio is low compared to industry peers. It might indicate the stock is undervalued or that the company’s assets are not expected to generate strong returns.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ZYME
Add Zymeworks Inc. to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ZYME